By Benjamin Chiou
Date: Wednesday 21 Jan 2026
(Sharecast News) - American healthcare and medical device giant Johnson & Johnson matched analysts' estimates with its fourth-quarter results, as earnings jumped on the back of improved sales of cancer and autoimmune drugs.
| Johnson & Johnson agrees to pay £13bn for Switze... | 28-Apr-2011 | The Independent |
| S&N DRIFTS AS BID HOPES SLIP | 19-Apr-2011 | Express & Star |
| J&J asks judge to dismiss kickback case | 08-Oct-2010 | Wall Street Journal |
| Genzyme Again Rejects Sanofi’s Bid | 08-Oct-2010 | New York Times |
| Johnson & Johnson buying vaccine maker Crucell | 07-Oct-2010 | USA Today |
| Currency | US Dollars |
| Share Price | $ 218.01 |
| Change Today | $ -0.20 |
| % Change | -0.09 % |
| 52 Week High | $219.57 |
| 52 Week Low | $145.27 |
| Volume | 730 |
| Shares Issued | 2,406.92m |
| Market Cap | $524,733m |
| RiskGrade | 87 |
| Strong Buy | 6 |
| Buy | 8 |
| Neutral | 12 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 26 |

You are here: research